Demonstrating the value of RWEA new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional Share XDemonstrating the value of RWEhttps://pharmaphorum.com/views-analysis-oncology/demonstrating-the-value-of-rwe/
Real world evidence, digital partnerships and the future of pharmaAhead of the eyeforpharma Awards we spoke to judge Jennifer Wong – AstraZeneca’s senior director, RWE strategy & Share XReal world evidence, digital partnerships and the future of pharmahttps://pharmaphorum.com/views-analysis-digital/real-world-evidence-digital-partnerships-and-the-future-of-pharma/
Transforming oncology with a pan-European approach to data sharingBetween genomic data, electronic health records and digital health tools, we have all the information we need to Share XTransforming oncology with a pan-European approach to data sharinghttps://pharmaphorum.com/views-analysis-oncology/transforming-oncology-with-a-pan-european-approach-to-data-sharing/
7th Annual IMPACCT: Real World EvidenceReturning for its 7th year, IMPACCT: Real World Evidence provides top innovators and leaders in the real world Share X7th Annual IMPACCT: Real World Evidencehttps://pharmaphorum.com/events/7th-annual-impacct-real-world-evidence/
Real-world evidence: the future is hereUse of real-world evidence is becoming increasingly common to aid the clinical development process and provide important data Share XReal-world evidence: the future is herehttps://pharmaphorum.com/r-d/views-analysis-r-d/real-world-evidence-the-future-is-here/
Join the dots or lose out, Syneos Health advises big pharmaPharma companies need to rethink how they communicate and share information and insights within their own organisations, according Share XJoin the dots or lose out, Syneos Health advises big pharmahttps://pharmaphorum.com/views-analysis-sales-marketing/join-the-dots-or-lose-out-syneos-health-advises-big-pharma/
Challenging the idea of valid dataWhat is valid patient data? Industry colleagues and I recently wrestled with that question at the CBI Patient Share XChallenging the idea of valid datahttps://pharmaphorum.com/views-and-analysis/challenging-the-idea-of-valid-data/
Company profile: EvideraData disruption and applying ‘enabled intelligence’ to convert the promise shown in clinical trials into real-world success. For Share XCompany profile: Eviderahttps://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/data-disruption-and-applying-enabled-intelligence/
Could digital technology revolutionise pharma in 2018?This year’s eyeforpharma conference in Barcelona outlined how 2018 could be a turning point for the industry. As Share XCould digital technology revolutionise pharma in 2018?https://pharmaphorum.com/views-and-analysis/digital-technology-revolutionise-pharma-2018/
